Insulet (PODD) Total Current Liabilities (2010 - 2026)
Insulet (PODD) posted Total Current Liabilities of $687.5 million for Q1 2026, up 1.09% on a QoQ basis from $680.1 million in Q4 2025, and up 32.11% year-over-year from $520.4 million in Q1 2025.
Insulet (PODD) Total Current Liabilities (2010 - 2026) Analysis & Trends
Insulet's Total Current Liabilities history runs 17 years deep, the most recent figure standing at $687.5 million for Q1 2026.
- Quarterly Total Current Liabilities rose 32.11% year-over-year to $687.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $687.5 million (up 32.11% YoY) and the FY2025 annual result came in at $680.1 million, up 28.71% from the prior year.
- Total Current Liabilities was $687.5 million for Q1 2026 at Insulet, up from $680.1 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $1.0 billion in Q2 2025 and bottomed at $215.0 million in Q1 2022.
- A 5-year average of $494.3 million and a median of $451.4 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Current Liabilities advanced 12.14% — and 2025, when it soared 107.84%.
- Insulet's Total Current Liabilities stood at $364.7 million in 2022, then gained by 23.72% to $451.2 million in 2023, then increased by 17.11% to $528.4 million in 2024, then increased by 28.71% to $680.1 million in 2025, then gained by 1.09% to $687.5 million in 2026.
- Business Quant data shows PODD's Total Current Liabilities at $687.5 million in Q1 2026, $680.1 million in Q4 2025, and $647.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 18.38 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 6.32 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 11.66 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 4.57 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 1.41 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 2.22 Bn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 8.53 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | 1.60 Bn |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 8.70 Bn |
| 10 | Insulet | 11.52 Bn | 11.04 Bn | 529.10 Mn | 687.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 687.50 Mn |
| Dec 31, 2025 | 680.10 Mn |
| Sep 30, 2025 | 647.70 Mn |
| Jun 30, 2025 | 1.01 Bn |
| Mar 31, 2025 | 520.40 Mn |
| Dec 31, 2024 | 528.40 Mn |
| Sep 30, 2024 | 506.20 Mn |
| Jun 30, 2024 | 486.00 Mn |
| Mar 31, 2024 | 432.40 Mn |
| Dec 31, 2023 | 451.20 Mn |
| Sep 30, 2023 | 451.40 Mn |
| Jun 30, 2023 | 425.00 Mn |
| Mar 31, 2023 | 383.30 Mn |
| Dec 31, 2022 | 364.70 Mn |
| Sep 30, 2022 | 334.20 Mn |
| Jun 30, 2022 | 279.30 Mn |
| Mar 31, 2022 | 215.00 Mn |
| Dec 31, 2021 | 228.80 Mn |
| Sep 30, 2021 | 228.60 Mn |
| Jun 30, 2021 | 213.30 Mn |